Predict your next investment

Hadean Ventures company logo
Venture Capital
FINANCIAL | Investment Firms & Funds

See what CB Insights has to offer


Private Equity | Alive

Total Raised


Last Raised

$17.54M | 4 yrs ago

About Hadean Ventures

Hadean Ventures combines an in-depth knowledge of medicine and life sciences, extensive investment experience at prestigious venture capital funds and strong track record of operational and hands-on management of start-ups.

Hadean Ventures Headquarter Location

Dronningen 1

Oslo, NO-0287,


+47 24115722

Latest Hadean Ventures News

Cardior Raises €64M in Series B Funding

Aug 25, 2021

Cardior Pharmaceuticals , a Hanover, Germany-based clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, closed a €64m ($76m) Series B financing round. The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds. In conjunction with the financing, representatives from Inkef Capital, Fund+ and Sunstone will join the Company’s Advisory Board. The company intends to use the funds for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline. Led by Dr. Claudia Ulbrich, Chief Executive Officer and Co-Founder, Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company advancing the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Its therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions.micro-RNAs are endogenous molecules that function as cellular regulators and their dysregulation contributes to the development of many diseases including cardiovascular diseases. Its lead candidate is CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132, intended to block the abnormal cardiac levels of micro-RNA-132 in heart failure patients thereby triggering a concerted therapeutic effect against key hallmarks of heart disease including cardiac hypertrophy, fibrosis, impaired contractility and reduced vascularization. FinSMEs 25/08/2021

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Hadean Ventures Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Hadean Ventures Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.